Back to products

Browse products

MedKoo product information:

Mifepristone

Mifepristone is a synthetic steroid compound used as a pharmaceutical. It is used as an abortifacient in the first two months of pregnancy, and in smaller doses as an emergency contraceptive. During early trials, it was known as RU-486, its designation at the Roussel Uclaf company, which designed the drug. The drug was initially made available in France, and other countries then followed—often amid controversy. It is marketed under tradenames Mifegyne and Mifeprex.

According to http://en.wikipedia.org/wiki/Mifepristone, the compound was discovered by researchers at Roussel Uclaf of France in 1980 (the "RU" in RU-486) while they were studying glucocorticoid receptor antagonists. Étienne-Émile Baulieu recognized its anti-progesterone activities and saw its potential for the induction of a medical abortion. Clinical testing began in 1982. The drug was first licensed in France in 1988, for use in combination with a prostaglandin, under the name Mifegyne.

Mifegyne is sold outside the U.S. by Exelgyn Laboratories, made in France, and is approved for:
1. Medical termination of intrauterine pregnancies of up to 49 days gestation (up to 63 days gestation in Britain and Sweden); 2. Softening and dilatation of the cervix prior to mechanical cervical dilatation for pregnancy termination; 3. Use in combination with gemeprost for termination of pregnancies between 13 and 24 weeks gestation; 4. Labor induction in fetal death in utero.

Mifeprex is sold in the U.S. by Danco Laboratories, made in China, and is U.S. Food and Drug Administration-approved to terminate intrauterine pregnancies of up to 49 days gestation.  see http://en.wikipedia.org/wiki/Mifepristone.  

Other medical applications of mifepristone that have been studied in Phase II clinical trials include regular long-term use as an oral contraceptive, and treatment of: uterine fibroids, endometriosis, major depression with psychotic features, glaucoma, meningiomas, breast cancer, ovarian cancer, and prostate cancer. Mifepristone has been used to treat Cushing's syndrome with treatment durations being as long as 10 years without noticeable adverse effect.

Current developer:    Corcept Therapeutics Inc

  1: Anderson PM, Tomaras M, McConnell K. Mifamurtide in osteosarcoma - a practical review. Drugs Today (Barc). 2010 May;46(5):327-37. PubMed PMID: 20517534.

2: Frampton JE. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs. 2010 Jun;12(3):141-53. doi: 10.2165/11204910-000000000-00000. PubMed PMID: 20481644.

3: Molecule of the month. Mifamurtide. Drug News Perspect. 2010 Apr;23(3):199. PubMed PMID: 20440421.

4: Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009 Aug;9(8):1035-49. Review. PubMed PMID: 19671023.

5: Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU 3rd, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA; Children's Oncology Group. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009 Nov 15;115(22):5339-48. PubMed PMID: 19637348; PubMed Central PMCID: PMC2783515.

6: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31. PubMed PMID: 18773127.

7: Dvoroznáková E, Porubcová J, Snábel V, Fedorocko P. Imunomodulative effect of

liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole. Parasitol Res. 2008 Sep;103(4):919-29. Epub 2008 Jun 29. PubMed PMID: 18587669.

8: Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D. 2008;9(2):131-5. Review. PubMed PMID: 18298131.

9: Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther. 2008 Feb;8(2):151-9. Review. PubMed PMID: 18279055.

10: Anderson P. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol. 2006 Jun;2(3):333-43. Review. PubMed PMID: 16787112.

11: Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP. Liposomal muramyl

tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets. 2006 Mar;6(2):123-33. Review. PubMed PMID: 16529542.

12: Romet-Lemonne JL, Mills B, Fridman WH, Munsell M. Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethanolamine in the treatment of osteosarcoma. J Clin Oncol. 2005 Sep 10;23(26):6437-8. PubMed PMID: 16155031.

13: Fedorocko P, Hoferová Z, Hofer M, Brezáni P. Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities. Neoplasma. 2003;50(3):176-84. PubMed PMID: 12937850.

14: Macková NO, Fedorocko P. Effect of liposomal muramyl tripeptide phosphatidylethanolamine and indomethacin on hematopoietic recovery in irradiated mice. Physiol Res. 2002;51(5):511-21. PubMed PMID: 12470204.

15: Worth LL, Jeha SS, Kleinerman ES. Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001 Aug;15(4):723-40, ix. Review. PubMed PMID: 11676281.

16: Klimp AH, De Vries EG, Scherphof GL, Daemen T. Chemo-immunotherapy of ovarian cancer in a murine tumour model. Anticancer Res. 2000 Jul-Aug;20(4):2585-92. PubMed PMID: 10953330.

17: Karpoff HM, Jarnagin W, Delman K, Fong Y. Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance. Surgery. 2000 Aug;128(2):213-8. PubMed PMID: 10922994.

18: Gianan MA, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm. 1998 Oct;13(5):363-8. PubMed PMID: 10851426.

19: Kurzman ID, Shi F, Vail DM, MacEwen EG. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm. 1999 Apr;14(2):121-8. PubMed PMID: 10850295.

20: Dieter P, Hempel U, Malessa B, Fitzke E, Tran-Thi TA, MacLouf J, Créminon C,

Kanaoka Y, Urade Y. Lipopolysaccharide- and liposome-encapsulated MTP-PE-induced

formation of eicosanoids, nitric oxide and tumor necrosis factor-alpha in macrophages. Adv Exp Med Biol. 1999;469:443-8. PubMed PMID: 10667366.

21: Eue I, Kumar R, Dong Z, Killion JJ, Fidler IJ. Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes. J Immunother. 1998 Sep;21(5):340-51. PubMed PMID: 9789196.

22: Durham RM, Lechner AJ, Johanns CA, Chen Z, Matuschak GM. Effect of MTP on TNF-alpha in perfused rat liver after bacteremia and ischemia/reperfusion. J Surg Res. 1998 May;76(2):179-84. PubMed PMID: 9698520.

23: Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1163-70. PubMed PMID: 9620075.

24: Teske E, Rutteman GR, vd Ingh TS, van Noort R, Misdorp W. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma. Anticancer Res. 1998 Mar-Apr;18(2A):1015-9. PubMed PMID: 9615757.

25: Obert M, Pleuger H, Hanagarth HG, Schulte-Mönting J, Wiesmüller KH, Braun DG, Brandner G, Hess RD. Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40 T antigen-derived peptide, K(698)-T(708). Vaccine. 1998 Jan-Feb;16(2-3):161-9. PubMed PMID: 9607025.

26: ten Hagen TL, van Vianen W, Savelkoul HF, Heremans H, Buurman WA, Bakker-Woudenberg IA. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or gamma interferon. Infect Immun. 1998 May;66(5):1962-7. PubMed PMID: 9573076; PubMed Central PMCID: PMC108150.

27: Macková NO, Fedorocko P. Effects of immunomodulators on postirradiation recovery in the thymus. Physiol Res. 1997;46(3):193-7. PubMed PMID: 9728506.

28: Dieter P, Ambs P, Fitzke E, Schwende H. Lipopolysaccharide and liposome-encapsulated MTP-PE-induced cytotoxicity and release of eicosanoids, tumor necrosis factor- alpha and nitric oxide in liver macrophages. Adv Exp Med Biol. 1997;407:485-90. PubMed PMID: 9321995.

29: Dzierzbicka K, Gozdowska M, Kołodziejczyk AM. [L-MTP-PE--a potential antineoplastic agent]. Postepy Hig Med Dosw. 1997;51(2):227-36. Review. Polish. PubMed PMID: 9235567.

30: Killion JJ, Bucana CD, Radinsky R, Dong Z, O'Reilly T, Bilbe G, Tarcsay L, Fidler IJ. Maintenance of intestinal epithelium structural integrity and mucosal

leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine. Cancer Biother Radiopharm. 1996 Dec;11(6):363-71. PubMed PMID: 10851497.

31: Fedorocko P, Macková NO. Combined modality radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of

liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin.

Int J Immunopharmacol. 1996 May;18(5):329-37. PubMed PMID: 8933212.

32: Goldbach P, Dumont S, Kessler R, Poindron P, Stamm A. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. Am J Physiol. 1996 Mar;270(3 Pt 1):L429-34. PubMed PMID: 8638735.

33: ten Hagen TL, Vossen AC, van Vianen W, Tibbe GJ, Savelkoul HF, Heremans H, Bakker-Woudenberg IA. Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice. Transplantation. 1995 Dec 15;60(11):1211-4. PubMed PMID: 8525512.

34: Passlick B, Labeta MO, Izbicki JR, Ostertag P, Löffler T, Siebeck M, Pichlmeier U, Schweiberer L, Ziegler-Heitbrock HW. Prevention of experimental endotoxin shock by a monocyte activator. Antimicrob Agents Chemother. 1995 Nov;39(11):2535-40. PubMed PMID: 8585740; PubMed Central PMCID: PMC162979.

35: Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine. 1995 Nov;13(16):1557-62. PubMed PMID: 8578842.

36: Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, London CA, Obradovich JE, Madewell BR, Rodriguez CO Jr, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res. 1995 Oct;1(10):1165-70. PubMed PMID: 9815908.

37: Wang L, Roos G, Stenram U. Adverse effects at adjuvant treatment of liver metastases in rat with RSU-1069 + microspheres, or liposomal MTP-PE. Anticancer Res. 1995 Sep-Oct;15(5B):2077-80. PubMed PMID: 8572605.

38: Dieter P, Ambs P, Fitzke E, Hidaka H, Hoffmann R, Schwende H. Comparative studies of cytotoxicity and the release of TNF-alpha, nitric oxide, and eicosanoids of liver macrophages treated with lipopolysaccharide and liposome-encapsulated MTP-PE. J Immunol. 1995 Sep 1;155(5):2595-604. PubMed PMID: 7650390.

39: Thomas K, Nijenhuis AM, Dontje BH, Daemen T, Scherphof GL. Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat. Clin Exp Metastasis. 1995 Sep;13(5):328-36. PubMed PMID: 7641418.

40: Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated

muramyl tripeptide. Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Review. PubMed PMID: 7490249.

41: Gano JB, Kleinerman ES. Liposomal MTP-PE: a promising new biologic response modifier. Oncol Nurs Forum. 1995 Jun;22(5):809-16. Review. PubMed PMID: 7675688.

42: Dinney CP, Tanguay S, Bucana CD, Eve BY, Fidler IJ. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma

growing in nude mice. J Interferon Cytokine Res. 1995 Jun;15(6):585-92. PubMed PMID: 7553228.

43: Galligioni E, Favaro D, Santarosa M, Quaia M, Spada A, Freschi A, Alberti D.

Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response. Clin Cancer Res. 1995 May;1(5):493-9. PubMed PMID: 9816008.

44: Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995 Apr;18(2):93-9. PubMed PMID: 7900714.

45: Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995 Apr;17(3):181-93. PubMed PMID: 7613644.

46: ten Hagen TL, van Vianen W, Bakker-Woudenberg IA. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. J Infect Dis. 1995 Feb;171(2):385-92. PubMed

PMID: 7844375.

47: Asano T, McIntyre BW, Bednarczyk JL, Wygant JN, Kleinerman ES. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol Res. 1995;7(5):253-7. PubMed PMID: 8534931.

48: Risin D, Kleinerman ES, Umezu Y, Pizzini RP, Balch CM, Pellis NR. Impairment

of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine. Cancer Immunol Immunother. 1995 Jan;40(1):57-64. PubMed PMID: 7828168.

49: Gano JB, Kleinerman ES. Administration of liposomal MTP-PE by the local physician: the role of the research nurse. Cancer Pract. 1995 Jan-Feb;3(1):42-6.

PubMed PMID: 7704060.

50: Fox LE, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Vail DM, Kisseberth W, London C, Madewell BR, Rodriguez CO Jr. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study. Cancer Biother. 1995 Summer;10(2):125-30. Erratum in: Cancer Biother 1995 Fall;10(3):249. PubMed PMID: 7663571.

51: Misúrová E, Fedorocko P. Influence of liposomal muramyl tripeptide phosphatidylethanolamine on the changes of nucleic acids in the blood and hemopoietic tissues of irradiated mice. Neoplasma. 1995;42(2):63-8. PubMed PMID:

7542365.

52: Tanguay S, Bucana CD, Wilson MR, Fidler IJ, von Eschenbach AC, Killion JJ. In vivo modulation of macrophage tumoricidal activity by oral administration of the

liposome-encapsulated macrophage activator CGP 19835A. Cancer Res. 1994 Nov 15;54(22):5882-8. PubMed PMID: 7954418.

53: Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS,

Dekker CL, Chernoff D. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine

in non-HIV-infected human volunteers. J Infect Dis. 1994 Nov;170(5):1288-91. PubMed PMID: 7963729.

54: Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G. The influence of

adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis. 1994 Nov;170(5):1110-9. PubMed PMID: 7963702.

55: Galligioni E, Santarosa M, Favaro D, Spada A, Talamini R, Quaia M. In vitro synergic effect of interferon gamma combined with liposomes containing muramyl tripeptide on human monocyte cytotoxicity against fresh allogeneic and autologous tumor cells. Tumori. 1994 Oct 31;80(5):385-91. PubMed PMID: 7839471.

56: Gano JB, Kleinerman ES. Liposomal MTP-PE. J Pediatr Oncol Nurs. 1994 Oct;11(4):161-3. Review. PubMed PMID: 7946146.

57: Bui T, Dykers T, Hu SL, Faltynek CR, Ho RJ. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein. J Acquir Immune Defic Syndr. 1994 Aug;7(8):799-806. PubMed PMID: 8021814.

58: Ding JW, Andersson R, Soltesz VL, Pärsson H, Johansson K, Wang W, Bengmark S. Inhibition of bacterial translocation in obstructive jaundice by muramyl tripeptide phosphatidylethanolamine in the rat. J Hepatol. 1994 Jun;20(6):720-8.

PubMed PMID: 7930471.

59: Killion JJ, Fidler IJ. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis. Immunomethods. 1994 Jun;4(3):273-9. Review. PubMed PMID: 7820457.

60: van de Water B, van Berkel TJ, Kuiper J. Activation of rat Kupffer cells to tumoricidal cells by the immunomodulator muramyl tripeptide-phosphatidylethanolamine incorporated into the novel drug carrier lactosylated low density lipoprotein. Mol Pharmacol. 1994 May;45(5):971-7. PubMed PMID: 8190111.

61: Fedorocko P. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse. Int J Radiat Biol. 1994 Apr;65(4):465-75. PubMed PMID: 7908934.

62: Asano T, McWatters A, An T, Matsushima K, Kleinerman ES. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther. 1994 Feb;268(2):1032-9. PubMed PMID: 8113959.

63: Asano T, Matsushima K, Kleinerman ES. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels. Cancer Immunol Immunother. 1994 Jan;38(1):16-22. PubMed PMID: 8299114.

64: Ho RJ, Burke RL, Merigan TC. Disposition of antigen-presenting liposomes in vivo: effect on presentation of herpes simplex virus antigen rgD. Vaccine. 1994;12(3):235-42. PubMed PMID: 8165856.

65: Melissen PM, van Vianen W, Bakker-Woudenberg IA. Treatment of Klebsiella pneumoniae septicemia in normal and leukopenic mice by liposome-encapsulated muramyl tripeptide phosphatidylethanolamide. Antimicrob Agents Chemother. 1994 Jan;38(1):147-50. PubMed PMID: 8141571; PubMed Central PMCID: PMC284413.

66: Verweij J, Judson I, Steward W, Coleman R, Woll P, van Pottelsberghe C, van Glabbeke M, Mouridsen H. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult.

An EORTC Soft Tissue and Bone Sarcoma Group study. Eur J Cancer. 1994;30A(6):842-3. PubMed PMID: 7917546.

67: Killion JJ, Brown DR, Wilson MR, Lloyd MM, Fidler IJ. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide. Oncol Res. 1994;6(8):357-64. PubMed PMID: 7894085.

68: Fox LE, King RR, Shi F, Kurzman ID, MacEwen EG, Kubilis PS. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats. Cancer Biother. 1994 Winter;9(4):329-40. PubMed PMID: 7719380.

69: MacEwen EG, Kurzman ID, Helfand S, Vail D, London C, Kisseberth W, Rosenthal

RC, Fox LE, Keller ET, Obradovich J, et al. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target. 1994;2(5):391-6. PubMed PMID: 7704483.

70: Kurzman ID, Cheng H, MacEwen EG. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine

monocyte activity. Cancer Biother. 1994 Summer;9(2):113-21. PubMed PMID: 7529085.

71: Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent

for cancer therapy. J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):286-92. PubMed PMID: 8280710.

72: Asano T, Fujimaki W, McWatters A, An T, Matsushima K, Kleinerman ES. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol Immunother. 1993 Nov;37(6):408-11. PubMed PMID: 8242665.

73: Bezault J, Walsh C, Tarcsay L, Frost H, Liebes L, Furmanski P. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs. In Vivo. 1993 Nov-Dec;7(6A):487-91. Erratum in: In Vivo.

2007 May-Jun;21(3):553. In Vivo. 2007 Nov-Dec;21(6):1172. PubMed PMID: 8193265.

74: Gay B, Cardot JM, Schnell C, van Hoogevest P, Gygax D. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE. J Pharm Sci. 1993 Oct;82(10):997-1001. PubMed PMID: 8254500.

75: Singh RK, Berry K, Matsushima K, Yasumoto K, Fidler IJ. Synergism between human monocyte chemotactic and activating factor and bacterial products for activation of tumoricidal properties in murine macrophages. J Immunol. 1993 Sep 1;151(5):2786-93. PubMed PMID: 8360492.

76: Kurzman ID, Shi F, MacEwen EG. In vitro and in vivo canine mononuclear cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide. Vet Immunol Immunopathol. 1993 Sep;38(1-2):45-56. PubMed PMID: 8256437.

77: Maeda M, Asano T, Kleinerman ES. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide. Cancer Immunol Immunother. 1993 Aug;37(3):203-8. PubMed PMID: 8334682.

78: Seger M, Gold D, Lengy J, Pauli H, Keisari Y. The schistosomulicidal activity and the production of IL-1 and TNF-alpha by peritoneal macrophages from infected

mice and their potentiation by muramyl tripeptide-phosphatidyl ethanolamine (MTP-PE) treatment. Parasite Immunol. 1993 Jun;15(6):339-47. PubMed PMID: 8361776.

79: Hoedemakers RM, Vossebeld PJ, Daemen T, Scherphof GL. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides. J Immunother Emphasis Tumor

Immunol. 1993 May 4;13(4):252-60. PubMed PMID: 8334109.

80: Teske E, Rutteman GR. Liposome-enhanced tumour therapy in canine mammary gland tumours. Tijdschr Diergeneeskd. 1993 Mar;118 Suppl 1:32S-33S. Review. PubMed PMID: 8480312.

81: Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? Cancer Immunol Immunother. 1993;36(1):45-51. PubMed PMID: 8422667.

82: Melissen PM, van Vianen W, Bidjai O, van Marion M, Bakker-Woudenberg IA. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE)

and interferon-y (IFN-y) in experimental infection with Listeria monocytogenes. Biotherapy. 1993;6(2):113-24. PubMed PMID: 8398570.

83: Macková NO, Fedorocko P. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation. Neoplasma. 1993;40(6):379-85. PubMed PMID: 8289971.

84: Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine. 1993;11(9):909-13. PubMed PMID: 8212835.

85: Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a

new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993;62:101-7. Review. PubMed PMID: 8096724.

86: Melissen PM, van Vianen W, Leenen PJ, Bakker-Woudenberg IA. Tissue distribution and cellular distribution of liposomes encapsulating muramyltripeptide phosphatidyl ethanolamide. Tissue and cellular distribution of

LE-MTPPE. Biotherapy. 1993;7(1):71-8. Erratum in: Biotherapy 1994;8(1):85. PubMed PMID: 8068486.

87: Landmann R, Obrist R, Denz H, Ludwig C, Frost H, Wesp M, Rordorf C, Towbin H, Gygax D, Tarcsay L, et al. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. Biotherapy.

1993;7(1):1-12. PubMed PMID: 8068481.

88: Fujimaki W, Itoh K, An T, Gano JB, Ross MI, Mansfield PF, Balch CM, Augustus

LB, Karkevitch DD, Johnston D, et al. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biother. 1993 Winter;8(4):307-18. PubMed PMID: 7804372.

89: Smith BW, Kurzman ID, Schultz KT, Czuprynski CJ, MacEwen EG. Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. Cancer Biother. 1993 Summer;8(2):137-44. PubMed PMID: 7804354.

90: Asao T, Shibata HR, Batist G, Brodt P. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin. Cancer Res. 1992 Nov 15;52(22):6254-7. PubMed PMID: 1423270.

91: Ullrich SE, Fidler IJ. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens. J Leukoc Biol. 1992 Nov;52(5):489-94. PubMed PMID: 1431559.

92: Melissen PM, van Vianen W, Bakker-Woudenberg IA. Roles of peripheral leukocytes and tissue macrophages in antibacterial resistance induced by free or

liposome-encapsulated muramyl tripeptide phosphatidylethanolamide. Infect Immun.

1992 Nov;60(11):4891-7. PubMed PMID: 1399000; PubMed Central PMCID: PMC258245.

93: Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992 Aug;10(8):1310-6. PubMed PMID: 1634921.

94: Picci P. Osteosarcoma and other cancers of bone. Curr Opin Oncol. 1992 Aug;4(4):674-80. Review. PubMed PMID: 1511023.

95: Seger M, Gold D, Lengy J, Pauli H, Keisari Y. On the interaction between macrophages and developmental stages of Schistosoma mansoni: effect of muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) treatment on mice survival and the

generation of schistosomulicidal macrophages. Parasite Immunol. 1992 Jul;14(4):355-69. PubMed PMID: 1437229.

96: de Vries EG, Mulder NH, Daemen T. Current state of liposome-complexed drugs in the treatment of cancer patients. Ann Oncol. 1992 Jun;3(6):419-21. PubMed PMID: 1498057.

97: Liebes L, Walsh CM, Chachoua A, Oratz R, Richards D, Hochster H, Peace D, Marino D, Alba S, Le Sher D, et al. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma. J Natl Cancer Inst. 1992 May 6;84(9):694-9. PubMed PMID: 1569602.

98: Ziegler-Heitbrock HW, Passlick B, Käfferlein E, Coulie PG, Izbicki JR. Protection against lethal pneumococcal septicemia in pigs is associated with decreased levels of interleukin-6 in blood. Infect Immun. 1992 Apr;60(4):1692-4.

PubMed PMID: 1548092; PubMed Central PMCID: PMC257049.

99: Dinney CP, Utsugi T, Fidler IJ, von Eschenbach AC, Killion JJ. Immunotherapy

of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon. Cancer Res. 1992 Mar 1;52(5):1155-61. PubMed PMID: 1531322.

100: Melissen PM, van Vianen W, Rijsbergen Y, Bakker-Woudenberg IA. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection. Infect Immun. 1992 Jan;60(1):95-101. PubMed PMID: 1729201; PubMed Central PMCID: PMC257508.

101: Frost H. MTP-PE in liposomes as a biological response modifier in the treatment of cancer: current status. Biotherapy. 1992;4(3):199-204. Review. PubMed PMID: 1599803.

102: Talmadge JE. The rational development of biological response modifiers. Biotherapy. 1992;4(3):177-8. PubMed PMID: 1599800.

103: Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R, Fidler IJ. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother. 1992;34(4):211-20. PubMed PMID: 1537053.

104: Sugarman SM, Perez-Soler R. Liposomes in the treatment of malignancy: a clinical perspective. Crit Rev Oncol Hematol. 1992;12(3):231-42. Review. PubMed PMID: 1497823.

105: Killion JJ, Kleinerman ES, Wilson MR, Tanaka M, Fidler IJ. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Oncol Res. 1992;4(10):413-8. PubMed PMID: 1292756.

106: Hockertz S, Franke G, Paulini I, Lohmann-Matthes ML. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes. J Interferon Res. 1991 Jun;11(3):177-85. PubMed PMID:

1919076.

107: Faradji A, Bohbot A, Schmitt-Goguel M, Dumont S, Eischen A, Wiesel ML, Stierle A, Follea G, Eber M, Bergerat JP, et al. Apheresis-elutriation program for adoptive immunotherapy with autologous activated monocytes in cancer patients. Int J Artif Organs. 1991 May;14(5):304-12. PubMed PMID: 1864656.

108: Gay B, Towbin H, Schnell C, Einsle K, Graf P, Gygax D. Direct chemiluminescence immunoassay (CLIA) for muramyl tripeptide phosphatidyl-ethanolamine in plasma. J Biolumin Chemilumin. 1991 Apr-Jun;6(2):73-80. PubMed PMID: 1882709.

109: Malik ST, Martin D, Hart I, Balkwill F. Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. Br J Cancer. 1991 Mar;63(3):399-403. PubMed PMID: 2003980; PubMed Central PMCID: PMC1971867.

110: Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration

on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol. 1991 Feb;9(2):259-67. PubMed PMID: 1988574.

111: Wintsch J, Chaignat CL, Braun DG, Jeannet M, Stalder H, Abrignani S, Montagna D, Clavijo F, Moret P, Dayer JM, et al. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis. 1991 Feb;163(2):219-25. PubMed PMID: 1988506.

112: Clark JW. Biological response modifiers. Cancer Chemother Biol Response Modif. 1991;12:193-212. Review. PubMed PMID: 1931443.

113: Utsugi T, Nii A, Fan D, Pak CC, Denkins Y, van Hoogevest P, Fidler IJ. Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Immunol Immunother. 1991;33(5):285-92. PubMed PMID: 1868486.

114: Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun. 1991;3(10-11):313-21. PubMed PMID: 1722107.

115: Shaw JM, Shaw KV. Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein-lipid carrier. Targeted Diagn Ther. 1991;5:351-83. PubMed PMID: 1665722.

116: Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han T, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J, et al. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J Biol Response Mod. 1990 Oct;9(5):492-8. PubMed PMID: 2254761.

117: Lazdins JK, Woods-Cook K, Walker M, Alteri E. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res Hum Retroviruses. 1990 Oct;6(10):1157-61. PubMed PMID: 1701314.

118: Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW 2nd, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, et al. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1990 May 15;50(10):2979-86. PubMed PMID: 1692252.

119: Skolnick A. Molecular biology research offers new weapons against cancer. JAMA. 1990 May 2;263(17):2289-90. PubMed PMID: 2109104.

120: Frost H, Murray JL, Chaudri HA, Van Damme J. Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. J Biol Response Mod. 1990 Apr;9(2):160-6. PubMed PMID: 2341859.

121: Sone S, Utsugi T, Tandon P, Yanagawa H, Okubo A, Ogura T. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients. Cancer Immunol Immunother. 1990;30(6):357-62. PubMed PMID: 2302725.

122: Kleinerman ES, Jaffe N. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma. Prog Clin Biol Res. 1990;343:263-79. PubMed PMID: 2198583.

123: Fidler IJ, Nii A, Utsugi T, Brown D, Bakouche O, Kleinerman ES. Differential release of TNF-alpha, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Lymphokine Res. 1990 Winter;9(4):449-63. PubMed PMID: 2090873.

124: Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga

J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin

Oncol. 1989 Dec;7(12):1915-25. PubMed PMID: 2479721.

125: Hockertz S, Franke G, Kniep E, Lohmann-Matthes ML. Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo. J Interferon Res. 1989 Oct;9(5):591-602. PubMed PMID:

2507661.

126: Izbicki JR, Ziegler-Heitbrock HW, Meier M, Lütticken R, Wilker DK, Siebeck M, Scheuber HP, Schweiberer L. The impact of splenectomy on antibody response in

the porcine model. J Clin Lab Immunol. 1989 Sep;30(1):13-9. PubMed PMID: 2641789.

127: Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1989 Aug 15;49(16):4665-70. PubMed PMID: 2787207.

128: Higgins PG, Barrow GI, Galbraith AW, Frost H, Tyrrell DA. A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2 infection in human volunteers. Antiviral Res. 1989 Aug;12(1):49-52. PubMed PMID: 2596839.

129: Ho RJ, Burke RL, Merigan TC. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs. J Virol. 1989 Jul;63(7):2951-8. PubMed PMID: 2542605; PubMed Central PMCID: PMC250849.

130: MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howard

PE. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989 Jun 21;81(12):935-8. PubMed PMID: 2733037.

131: Wachsmuth ED, Huber J. Stimulant effect of the immunomodulator MTP-PE on proliferation of monocytic cells in the guinea pig. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;58(1):45-57. PubMed PMID: 2574515.

132: Fidler IJ, Fan D, Ichinose Y. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Invasion Metastasis. 1989;9(2):75-88. PubMed PMID: 2496047.

133: Landmann R, Wesp M, Dukor P. Modulation of interferon-gamma-induced major histocompatibility (MHC) and CD14 antigen changes by lipophilic muramyltripeptide MTP-PE in human monocytes. Cell Immunol. 1988 Nov;117(1):45-55. PubMed PMID: 2460255.

134: Sanchez-Pescador L, Burke RL, Ott G, Van Nest G. The effect of adjuvants on

the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol. 1988 Sep 1;141(5):1720-7. PubMed PMID: 2842401.

135: Shaw JM, Futch WS Jr, Schook LB. Induction of macrophage antitumor activity

by acetylated low density lipoprotein containing lipophilic muramyl tripeptide. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6112-6. PubMed PMID: 3413079; PubMed Central PMCID: PMC281915.

136: Brownbill AF, Schumann G. MTP-PE: induction of tumoricidal leukocytes in the lungs of rats. Cancer Detect Prev. 1988;12(1-6):161-8. PubMed PMID: 3180123.

137: Mihich E. Biological response modifiers in cancer therapeutics: potentialities and limitations. Cancer Detect Prev. 1988;12(1-6):531-5. Review. PubMed PMID: 3052839.

138: Wachsmuth ED. Stimulation of cell proliferation in rabbits by MTP-PE, a lipophilic muramyl peptide. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;54(4):195-206. PubMed PMID: 2895530.

139: Fidler IJ, Fogler WE, Brownbill AF, Schumann G. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J Immunol.

1987 Jun 15;138(12):4509-14. PubMed PMID: 3584979.

140: Yamagami S, Brownbill AF, Schumann G. Induction of tumouricidal macrophages

by MTP-PE: its enhancement by a factor produced spontaneously by tumour cells. Cell Biol Int Rep. 1987 Jun;11(6):465-76. PubMed PMID: 3621354.

141: LeGrue SJ, Saiki I, Romerdahl CA, Fidler IJ. Systemic macrophage activation

by liposomes containing MTP-PE in mice immunosuppressed with cyclosporine. Transplantation. 1987 Apr;43(4):584-6. PubMed PMID: 3576675.

142: Fogler WE, Fidler IJ. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. Int J Immunopharmacol. 1987;9(2):141-50. PubMed PMID: 3583507.

143: Meyer T, Fabbro D, Eppenberger U, Matter A. The lipophilic muramyltripeptide MTP-PE, a biological response modifier, is an activator of protein kinase C. Biochem Biophys Res Commun. 1986 Nov 14;140(3):1043-50. PubMed PMID: 3465326.

144: Saiki I, Milas L, Hunter N, Fidler IJ. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide. Cancer Res. 1986 Oct;46(10):4966-70. PubMed PMID: 3756858.

145: Tandon P, Utsugi T, Sone S. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide. Cancer Res. 1986 Oct;46(10):5039-44. PubMed PMID: 3489519.

146: Meyer T, Dietrich FM, Walker MR, Hochkeppel HK. Antagonism of interferon induction in spleen and adherent peritoneal cells of mice by the lipophilic antiviral muramyl peptide MTP-PE. J Interferon Res. 1986 Jun;6(3):183-8. PubMed PMID: 2427620.

147: Sone S, Utsugi T, Tandon P, Ogawara M. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state. Cancer Immunol Immunother. 1986;22(3):191-6. PubMed PMID: 3731204.

148: Fidler IJ. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol Immunother. 1986;21(3):169-73. PubMed PMID: 3698058.

149: Nayar R, Schroit AJ, Fidler IJ. Liposome encapsulation of muramyl peptides for activation of macrophage cytotoxic properties. Methods Enzymol. 1986;132:594-603. PubMed PMID: 3547028.

150: Mutsuura S, Sone S, Tsubura E, Tachibana K, Kishino Y. Activation of antitumor properties in alveolar macrophages from protein-calorie malnourished rats. Cancer Immunol Immunother. 1986;21(1):63-8. PubMed PMID: 3080228.

151: Dietrich FM, Hochkeppel HK, Lukas B. Enhancement of host resistance against

virus infections by MTP-PE, a synthetic lipophilic muramyl peptide--I. Increased

survival in mice and guinea pigs after single drug administration prior to infection, and the effect of MTP-PE on interferon levels in sera and lungs. Int J Immunopharmacol. 1986;8(8):931-42. PubMed PMID: 2433236.

152: Sone S. Role of alveolar macrophages in pulmonary neoplasias. Biochim Biophys Acta. 1986;823(3):227-45. Review. PubMed PMID: 2423125.

153: Galbraith AW. Influenza--recent developments in prophylaxis and treatment. Br Med Bull. 1985 Oct;41(4):381-5. Review. PubMed PMID: 3902144.

154: Koff WC, Showalter SD, Hampar B, Fidler IJ. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide. Science. 1985 Apr 26;228(4698):495-7. PubMed PMID: 2984772.

155: Koff WC, Fidler IJ, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science. 1984 Jun 1;224(4652):1007-9.

PubMed PMID: 6426057.

156: Schroit AJ, Fidler IJ. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases. Prog Clin Biol Res. 1982;102 pt A:347-55. PubMed PMID: 7167445.

1: Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol. 2004 Jan;18(1):70-85. Epub 2003 Oct 30. PubMed PMID: 14593076.

2: Check JH, Dix E, Cohen R, Check D, Wilson C. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res. 2010 Feb;30(2):623-8. PubMed PMID: 20332480.

3: Check JH, Sansoucie L, Chern J, Dix E. Mifepristone treatment improves length

and quality of survival of mice with spontaneous lung cancer. Anticancer Res. 2010 Jan;30(1):119-22. PubMed PMID: 20150625.

4: Saha P, Hödl C, Strauss WS, Steiner R, Goessler W, Kunert O, Leitner A, Haslinger E, Schramm HW. Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in

human breast cancer cells. Bioorg Med Chem. 2010 Mar 1;18(5):1891-8. Epub 2010 Jan 25. PubMed PMID: 20149664.

5: Im A, Appleman LJ. Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert Opin Pharmacother. 2010 Feb;11(3):481-8. Review. PubMed PMID: 20102310.

6: Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J, Mannel RS. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010 Mar;116(3):332-4. Epub 2009 Nov 17. PubMed PMID: 19922989.

7: Luo X, Yin P, Reierstad S, Ishikawa H, Lin Z, Pavone ME, Zhao H, Marsh EE, Bulun SE. Progesterone and mifepristone regulate L-type amino acid transporter 2

and 4F2 heavy chain expression in uterine leiomyoma cells. J Clin Endocrinol Metab. 2009 Nov;94(11):4533-9. Epub 2009 Oct 6. PubMed PMID: 19808856; PubMed Central PMCID: PMC2775649.

8: Jurado R, Lopez-Flores A, Alvarez A, García-López P. Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep. 2009 Nov;22(5):1237-45. PubMed PMID: 19787245.

9: Check JH, Sansoucie L, Chern J, Amadi N, Katz Y. Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia. Anticancer Res. 2009 Aug;29(8):2977-80. PubMed PMID: 19661303.

10: Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):215-8. Epub 2009 Jul 7. PubMed PMID:

19586708.

11: Fraser IS. Re: Low-dose mifepristone: Effects on the endometrium. Aust N Z J

Obstet Gynaecol 2009; 49: 77-83. Aust N Z J Obstet Gynaecol. 2009 Jun;49(3):342.

PubMed PMID: 19566579.

12: Radcliffe PM, Sterling CR, Tank AW. Induction of tyrosine hydroxylase mRNA by nicotine in rat midbrain is inhibited by mifepristone. J Neurochem. 2009 Jun;109(5):1272-84. Epub 2009 Mar 23. PubMed PMID: 19476543; PubMed Central PMCID: PMC2731240.

13: Check JH, Dix E, Sansoucie L, Check D. Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report. Anticancer Res. 2009 May;29(5):1611-3. PubMed PMID: 19443374.

14: Moe BG, Vereide AB, Orbo A, Sager G. High concentrations of progesterone and

mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. Anticancer Res. 2009 Apr;29(4):1053-8. PubMed PMID: 19414345.

15: Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G. Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res. 2009 Apr;29(4):1047-52. PubMed PMID: 19414344.

16: Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009 Aug;24(8):1870-9. Epub 2009 Apr 23. PubMed PMID: 19389793.

17: Tamura T, Yokoi R, Okuhara Y, Harada C, Terashima Y, Hayashi M, Nagasawa T, Onozato T, Kobayashi K, Kuroda J, Kusama H. Collaborative work on evaluation of ovarian toxicity. 2) Two- or four-week repeated dose studies and fertility study

of mifepristone in female rats. J Toxicol Sci. 2009;34 Suppl 1:SP31-42. PubMed PMID: 19265287.

18: Erenbourg A, Piccoli M, Ronfani L, Tamburlini G. Mifepristone for the treatment of uterine leiomyomas: methodological issues and clinical implications. Obstet Gynecol. 2009 Mar;113(3):741; author reply 741. PubMed PMID: 19300345.

19: Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):77-83. PubMed PMID: 19281585.

20: Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 2009 May 1;115(9):1867-74. PubMed PMID: 19241422.

21: Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM. Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Cancer Cell Int. 2009 Feb 17;9:4. PubMed PMID: 19222856; PubMed Central PMCID: PMC2661041.

22: Hödl C, Raunegger K, Strommer R, Ecker GF, Kunert O, Sturm S, Seger C, Haslinger E, Steiner R, Strauss WS, Schramm HW. Syntheses and antigestagenic activity of mifepristone derivatives. J Med Chem. 2009 Mar 12;52(5):1268-74. PubMed PMID: 19216549.

23: Freeburg EM, Goyeneche AA, Telleria CM. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol. 2009 Mar;34(3):743-55. PubMed PMID: 19212679; PubMed Central PMCID: PMC2690705.

24: Ørbo A, Moe BT, Grønaas H, Paulssen RH. Early effects of high concentrations

of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa). J Steroid Biochem Mol Biol. 2009 Jan;113(1-2):139-49. Epub 2008 Dec 24. PubMed PMID: 19138738.

25: Yague JG, Garcia-Segura LM, Azcoitia I. Selective transcriptional regulation

of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells. Endocrine. 2009 Apr;35(2):252-61. Epub 2008 Dec 31. PubMed PMID: 19116788.

26: Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2008 Nov;112(5):1029-36. PubMed PMID: 18978102.

27: Liu Y, Wang LL. [Mifepristone modulates glucosylceramide synthase expression

and reverse multidrug resistance in ovarian cancer cells]. Nan Fang Yi Ke Da Xue

Xue Bao. 2008 Aug;28(9):1727-30. Chinese. PubMed PMID: 18819906.

28: Zhou H, Ohno N, Terada N, Saitoh S, Naito I, Ohno S. Permselectivity of blood follicle barriers in mouse ovaries of the mifepristone-induced polycystic ovary model revealed by in vivo cryotechnique. Reproduction. 2008 Nov;136(5):599-610. Epub 2008 Aug 21. PubMed PMID: 18719066.

29: Liu GY, Qu QX, Mi RR, Qi J. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells]. Zhonghua Fu Chan Ke Za Zhi. 2008 Feb;43(2):132-5. Chinese. PubMed PMID: 18683754.

30: Engman M, Skoog L, Söderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod. 2008 Sep;23(9):2072-9. Epub

2008 Jun 24. PubMed PMID: 18579510.

31: Malartic C, Morel O, Akerman G, Tulpin L, Desfeux P, Barranger E. [Role of mifepristone for the treatment of uterine fibroid]. Gynecol Obstet Fertil. 2008 Jun;36(6):668-74. Epub 2008 Jun 9. Review. French. PubMed PMID: 18539512.

32: Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May;101(9):1084-9. PubMed PMID: 18399827.

33: Cassier PA, Abou-Amara-Olivieri S, Artru P, Lapalus MG, Riou JP, Lombard-Bohas C. Mifepristone for ectopic ACTH secretion in metastatic endocrine

carcinomas: report of two cases. Eur J Endocrinol. 2008 Jun;158(6):935-8. Epub 2008 Apr 7. PubMed PMID: 18390992.

34: Navo MA, Smith JA, Gaikwad A, Burke T, Brown J, Ramondetta LM. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486)

in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol. 2008 Aug;62(3):483-9. Epub 2007 Nov 15. PubMed PMID: 18004570.

35: Srivastava MD, Thomas A, Srivastava BI, Check JH. Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma. 2007 Aug;48(8):1610-7. PubMed PMID: 17701593.

36: Goyeneche AA, Carón RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007 Jun 1;13(11):3370-9. PubMed PMID: 17545545; PubMed Central PMCID: PMC2505183.

37: Koivisto-Korander R, Leminen A, Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstet Gynecol.

2007 Feb;109(2 Pt2):512-4. PubMed PMID: 17267877.

38: Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006 Dec;24(8):727-33. PubMed PMID: 17162554.

39: Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006 Dec;108(6):1381-7. PubMed PMID: 17138770.

40: Zhang H, Lü JJ, Gao QZ, Zhang J. [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro]. Zhonghua Wai Ke Za Zhi. 2006 Mar 15;44(6):382-5. Chinese. PubMed PMID: 16638347.

41: Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G, Daraï E. Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep. 2006 Apr;15(4):743-8. PubMed PMID: 16525653.

42: Gary MM, Harrison DJ. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother. 2006 Feb;40(2):191-7. Epub 2005 Dec 27. PubMed PMID: 16380436.

43: Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005 Dec;84(6):1719-26. PubMed PMID: 16359971.

44: Li A, Felix JC, Minoo P, Amezcua CA, Jain JK. Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil

Steril. 2005 Jul;84(1):202-11. PubMed PMID: 16009178.

45: Milewicz T, Gregoraszczuk EL, Sztefko K, Augustowska K, Krzysiek J, Ryś J. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486). Growth Horm IGF Res. 2005 Apr;15(2):140-7. PubMed PMID: 15809018.

46: Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, Balk SP, Hollenberg AN. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem. 2005 Feb 25;280(8):6511-9. Epub 2004 Dec 14. PubMed PMID: 15598662.

47: Mirkin S, Archer DF. Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone. Contraception. 2004 Oct;70(4):327-33. PubMed PMID: 15451338